Co-Diagnostics, Inc. (CODX) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Thank you for standing by. At this time, I would like to welcome everyone to the Co-Diagnostics, Inc., second quarter 2026 earnings webcast. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press star followed by the number one on your telephone keypad. I would now like to turn the conference over to Andrew Benson, Head of Investor Relations. The floor is yours. Good afternoon, everyone. Thank you all for participating in today's conference call. On the line today from CoDiagnostics, we have Dwight Egan, Chief Executive Officer, and Brian Brown, Chief Financial Officer. Earlier today, CoDiagnostics released financial results from the second quarter ended June 30, 2026. A copy of the press release is available on the company's website. We will begin with management's prepared remarks and then open up the call to analyst Q&A. Before we begin, we would like to inform listeners that certain statements made by co-diagnostics during this call, which are not historical facts, are forward-looking statements. In addition to diagnostic test developments and clinical evaluation timelines, this includes statements concerning regulatory review and clearance, commercialization plans and timing, international regulatory and manufacturing initiatives, financing and liquidity, and the capabilities and potential uses of the company's technology and data infrastructure. The company's Codex PCR testing platform and related tests are subject to regulatory review, clearance or authorization and are not currently for sale. Actual outcomes and results may differ materially from what is expressed or implied in any statement. Important facto...